GondolaBio is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, that develops therapies for genetic and rare diseases. Launched in 2024 as a spinout of BridgeBio Pharma, it applies a lean, decentralized approach to early-stage research and development, targeting diseases with clear genetic markers and few approved treatment options. Its public pipeline spans discovery through Phase 2 programs across multiple modalities.

The company's lead program PORT-77 is an oral small molecule in Phase 2 development for erythropoietic protoporphyria and X-linked protoporphyria, advanced through its affiliate Portal Therapeutics, and it holds U.S. FDA Orphan Drug and Fast Track designations for that indication. GondolaBio also advances a hereditary pancreatitis program in lead optimization that addresses an estimated 30,000 patients in the United States and European Union.